References
- Braun J, Rau R. An update on methotrexate. Curr Opin Rheumatol 2009;21:216–23.
- National Institute for Health and Clinical Excellence. Rheumatoid arthritis: the management of rheumatoid arthritis in adults. NICE Clinical Guideline CG 79, February 2009.
- Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–75.
- Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, . 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625–39.
- Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, . Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108:1362–70.
- Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, . The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010;49:295–307.
- Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690–7.
- Mainman H, McClaren E, Heycock C, Saravanan V, Hamilton J, Kelly C. When should we use parenteral methotrexate? Clin Rheumatol 2010;29:1093–8.
- Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004;31:645–8.
- Braun J, Kastner P, Flaxenberg P, Währisch J, Hanke P, Demary W, . Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2008;58:73–81.
- Rutkowska-Sak L, Rell-Bakalarska M, Lisowska B. Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. Reumatologia 2009;47:207–11.
- Fitzpatrick RW, Scott DGI, Keary I. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate. Clin Rheumatol 2013;32:1605–12.
- Hassanzadeh R, Mangan C, France J, Bawa S. Subcutaneous methotrexate to cut costs? J Rheumatol 2012;39:1764–5.
- Striesow F, Brandt A. Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskelet Dis 2012;4:3–9.
- Bingham SJ, Buch MH, Lindsay S, Pollard A, White J, Emery P. Parenteral methotrexate should be given before biological therapy. Rheumatology 2003;42:1009–10.
- Griffin AJ, Erkeller-Yuksel F. Parenteral methotrexate should be given before biological therapy. Rheumatology 2004;43:678.
- Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, . Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012;39:1559–82.
- Kapral T, Stamm T, Machold KP, Montag K, Smolen JS, Aletaha D. Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure. Arthritis Res Ther 2006;8:R46.
- Bingham SJ, Buch MH, Emery P. Reply: Parenteral methotrexate should be given before biological therapy. Rheumatology 2004;43:678–9.
- Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, . Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086–93.
- National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. Technical appraisal 130. Available from: www.nice.org.uk/Guidance/TA130 (accessed August 2012).
- Deighton C, Hyrich K, Ding T, Ledingham J, Lunt M, Luqmani R, . BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology 2010;49:1197–9.